Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAL vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Tralokinumab is a human monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits. This blockade reduces IL-13-mediated signaling, which is implicated in the pathophysiology of atopic dermatitis, including inflammation, pruritus, and skin barrier dysfunction.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
10 mg intravenously once daily
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life is 12–18 hours in patients with normal renal function (Cr Cl >90 m L/min). In moderate renal impairment (Cr Cl 30–59 m L/min), half-life extends to 24–36 hours. Clinical context: Dosing interval adjustment required for Cr Cl <60 m L/min.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Tralokinumab is a monoclonal antibody, expected to be degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes are involved.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion; 30% is eliminated in feces via biliary secretion. Total renal clearance accounts for 85% of systemic clearance.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
92% bound primarily to human serum albumin; minor binding to alpha-1-acid glycoprotein (3%). Binding is concentration-independent over therapeutic range.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Vd is 0.25 L/kg (range 0.2–0.3 L/kg), indicating distribution primarily into extracellular fluid. Vd increases to 0.4 L/kg in patients with edema or ascites.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral bioavailability is 60–75% due to first-pass hepatic metabolism; 90–100% for intramuscular and subcutaneous routes.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
No dose adjustment required for GFR ≥30 m L/min; not recommended for GFR <30 m L/min
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No dose adjustment for Child-Pugh A; use with caution for Child-Pugh B and C, no specific dose recommendation
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Not approved for pediatric use; safety and efficacy not established
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
No specific dose adjustment; monitor renal function closely in elderly patients
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
None.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Hypersensitivity reactions (including anaphylaxis) have been reported; discontinue if serious reaction occurs.,Patients with parasitic (helminth) infections should be treated before initiating therapy; monitor during treatment.,Potential for increased risk of infections; consider risks in patients with chronic infections or history of recurrent infections.,Consider vaccination status prior to initiation; avoid live vaccines during treatment.
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Known hypersensitivity to tralokinumab or any excipients in the formulation.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
No specific food interactions known; take with or without food. Grapefruit may alter metabolism; advise limiting grapefruit juice intake.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
TRAL is a monoclonal antibody. No human data available; animal studies did not show teratogenicity at clinically relevant doses. Due to Ig G1 transport across placenta, potential exposure in second and third trimesters. Theoretical risk of immunosuppression in the fetus.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
TRAL is a large monoclonal antibody likely excreted in breast milk in small amounts. M/P ratio not established. Limited data; consider risk-benefit; use caution.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No pharmacokinetic studies in pregnancy. No dose adjustment recommended; weight-based dosing may need adjustment for maternal weight gain, but specific data lacking.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
TRAL is a novel anti-epileptic drug with linear pharmacokinetics; monitor for somnolence, dizziness, and weight gain; adjust dose in renal impairment (Cr Cl < 30 m L/min). Avoid abrupt discontinuation; taper over 2-4 weeks. Drug interactions: induces CYP3A4 and may reduce efficacy of oral contraceptives; valproate increases TRAL levels by 40%.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take exactly as prescribed; do not stop suddenly without medical advice.,Avoid driving or operating heavy machinery until you know how this medicine affects you.,Report any rashes, swelling, or mood changes immediately.,Use effective contraception; this drug may reduce birth control effectiveness.,Avoid alcohol while taking this medication.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
"Concurrent use of lorazepam, a benzodiazepine, and sertraline, a selective serotonin reuptake inhibitor (SSRI), may result in additive central nervous system (CNS) depression, leading to enhanced sedation, dizziness, and psychomotor impairment. This interaction is primarily pharmacodynamic, involving potentiation of GABAergic effects by lorazepam and sertraline's modulation of serotonergic pathways, which can augment sedative effects. Clinically, patients may experience excessive drowsiness, reduced cognitive function, and increased risk of falls or accidents, particularly during treatment initiation or dose adjustments."
"Axitinib, a tyrosine kinase inhibitor used in renal cell carcinoma, is primarily metabolized by CYP3A4 and also inhibits CYP3A4 and CYP2D6. Sertraline, an SSRI antidepressant, is a substrate of CYP2D6 and to a lesser extent CYP3A4. Coadministration may lead to decreased clearance of sertraline, resulting in elevated sertraline plasma concentrations and increased risk of serotonin-related adverse effects such as serotonin syndrome, QT prolongation, or gastrointestinal disturbances."
"Mequitazine, a first-generation H1-antihistamine, inhibits CYP2D6 and CYP3A4, the primary enzymes responsible for the metabolism of sertraline, a selective serotonin reuptake inhibitor (SSRI). This inhibition can significantly reduce sertraline clearance, leading to increased plasma concentrations, which may elevate the risk of dose-dependent adverse effects such as serotonin syndrome, QT prolongation, and central nervous system depression. Patients may present with symptoms including confusion, tachycardia, hyperthermia, or arrhythmias, particularly at higher doses or in those with underlying risk factors."
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAL vs ALFENTA, answered by our medical review team.
TRAL is a Opioid Analgesic that works by Tralokinumab is a human monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its interaction with the IL-13 receptor α1 and α2 subunits. This blockade reduces IL-13-mediated signaling, which is implicated in the pathophysiology of atopic dermatitis, including inflammation, pruritus, and skin barrier dysfunction.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAL and ALFENTA depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAL is: 10 mg intravenously once daily. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAL and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAL is classified as Category C. TRAL is a monoclonal antibody. No human data available; animal studies did not show teratogenicity at clinically relevant doses. Due to IgG1 transport across placenta, potential ex. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.